ClinicalTrials.gg
CompletedNCT01186861Updated Nov 18, 2025

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

A Phase 2 interventional study of OSI-906 and erlotinib in Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy, sponsored by Astellas Pharma Inc. Completed at 69 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Carcinoma, Non-Small-Cell Lung by Astellas Pharma Inc — 5 open to participants now, 7 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Astellas Pharma Inc.

Enrollment
10th of 29
205 · median 103
Started
2011
with 1 other
Phase 2
9 of 29
none open now
Registered
12th of 29
by date

Among the 29 studies in Carcinoma, Non-Small-Cell Lung by Astellas Pharma Inc, this one is the 10th largest by enrollment, is one of 2 that started in 2011, is one of 9 in phase 2, and was the 12th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 29 studies in Carcinoma, Non-Small-Cell Lung by Astellas Pharma Inc are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Carcinoma, Non-Small-Cell Lung by Astellas Pharma Inc, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, placebo-controlled, phase 2 study with a 1:1 randomization scheme.

Read the detailed description

Adult patients with advanced Non-small Cell Lung Cancer (NSCLC) and nonprogression after platinum-based chemotherapy will be randomized 1:1 to receive either OSI-906 plus erlotinib or placebo plus erlotinib.

03

Conditions studied

  • Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Keywords

  • OSI-906
  • Erlotinib
  • Platinum-based chemotherapy
  • Placebo
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed locally advanced or stage IIIB or IV NSCLC
  • Have experienced Complete Response (CR), Partial Response (PR) or Stable Disease (SD) following completion of 4 cycles of platinum-based chemotherapy and are not progressing at time of entry into study (prior completed first-line combination bevacizumab therapy is permitted; however, current use of maintenance bevacizumab is not permitted. A maximum interval of 28 days between the last day of the treatment cycle and randomization
  • Patient has recovered from prior chemotherapy-related toxicity to ≤ grade 2
  • EGFR mutation status must be confirmed for participation in the study. EGFR analysis can be performed either by central or local laboratory. If analysis is done locally, verifiable documentation confirming the EGFR mutation status must be submitted for review and approval by APGD prior to randomization. If no local result is available, formalin-fixed, paraffin-embedded representative of the tumor or in the absence of archival tissue, a fresh tumor tissue sample of sufficient size to perform EGFR mutation analysis must be submitted centrally. Results of the central analysis must be available prior to randomization. Additionally, subjects should provide tissue blocks centrally for biomarker analysis whenever possible. Ideal tissue requirement: block with ≥5 mm2 tumor area sufficient to provide four 4-micron, and five 10-micron sections)
  • (for those patients with PR or SD after first-line platinum-based chemotherapy) according to (RECIST) (version 1.1)
  • (ECOG) Performance Status(PS) 0 - 1
  • Previous or neo-adjuvant treatment is permitted
  • Must be able to take oral medication
  • Fasting glucose ≤ 150 mg/dL (8.3 mmol/L). Concurrent use of non-insulinotropic antihyperglycemic therapy is permitted if the dose has been stable for ≥ 4 weeks at the time of randomization
  • Adequate hematopoietic, hepatic, and renal function defined as follows:

    • ≥ 1.5 x 109/L
    • count ≥ 100 x 109/L
    • ≤ 1.5 x (ULN)
    • and ALT ≤ 2.5 x ULN, or ≤ 5 x ULN if patient has documented liver metastases
    • Serum creatinine ≤ 1.5 x ULN
  • Potassium, magnesium and calcium within normal limits (supplementation and retesting is permitted)

Female patient must be either:

  • Of non child bearing potential:

    • (defined as at least 1 year without any menses) prior to

Screening, or

  • documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening)

    • Or, if of :
  • must have a negative urine pregnancy test at Screening, and
  • must use two forms of (one of which must be a barrier method) starting at Screening and throughout the study period and for 30 days after final study drug administration

    • Female patient must not be breastfeeding at Screening or during the study period and for 30 days after final study drug administration
    • Female patient must not donate ova starting at Screening and throughout the study period and for 30 days after final study drug administration
    • Male patient and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continue throughout the study period and for 30 days after final study drug administration
    • Male patient must not donate sperm starting at Screening and throughout the study period and for at least 30 days after final study drug administration
    • Prior radiation therapy is permitted provided patients have recovered from acute toxic effects of radiotherapy prior to randomization. A minimum of 28 days must have elapsed between the end of radiotherapy and randomization
    • Prior surgery is permitted provided that the surgery was performed 21 days prior to randomization and adequate wound healing has occurred prior to randomization
    • Patients must provide written (signed) to participate in the study and for use of tumor tissues

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to agents directed at the Human Epidermal Receptor (HER) axis (eg, erlotinib, gefitinib, cetuximab, and trastuzumab)
  • other than NSCLC within past 3 years (exceptions if curatively treated: basal or squamous cell carcinoma of skin; locally advanced prostate cancer; ductal carcinoma in situ of breast; in situ cervical carcinoma; and superficial bladder cancer)
  • Type 1 diabetes mellitus or Type 2 diabetes mellitus currently requiring insulinotropic or insulin therapy
  • Prior insulin-like growth factor receptor (IGF-1R)
  • Prior agent within 21 days prior to randomization
  • Concurrent use of maintenance bevacizumab
  • History of poorly controlled gastrointestinal disorders that could affect the absorption of study drug (eg, Crohn's disease, ulcerative colitis, etc)
  • History (within last 180 days) of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac disease includes second/third degree heart block; ischemic heart disease; superior vena cava (SVC) syndrome; poorly controlled hypertension; congestive heart failure of (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea)
  • History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment (≥ grade 3), left bundle branch block (LBBB), or asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation controlled by medication are not excluded
  • Mean interval > 450 msec based on independent central reviewer analysis of screening visit ECGs
  • Use of drugs that have a known risk of causing Torsades de Pointes (TdP) are prohibited within 14 days prior to randomization
  • Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine. Other less potent CYP1A2 inhibitors/inducers are not excluded
  • Use of potent inhibitor such as ketoconazole, clarithromycin, atazanavir, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), or voriconazole
  • Use of proton pump inhibitors such as omeprazole. Use of H2-receptor antagonists such as ranitidine are not excluded
  • History of cerebrovascular accident (CVA) within 180 days prior to randomization or that resulted in ongoing neurologic instability
  • Active infection, serious underlying medical condition (including any type of active seizure disorder within 12 months prior to randomization), or serious chronic illness that would impair the ability of the patient to receive study drug
  • History of any psychiatric or neurologic condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide
  • Pregnant or breast-feeding females
  • Symptomatic that are not stable, require , or that have required radiation and/or other related treatment (e.g., anti-epileptic medication) within 21 days prior to randomization
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drug
  • Participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half lives whichever is longer, prior to the initiation of Screening or during the course of the study
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
205 participants (actual)

Study arms

  • Experimental
    Arm A: OSI-906 plus erlotinib

    OSI-906 150 mg twice daily (BID) starting on Day 1; erlotinib 150 mg once daily (QD) starting on Day 1

    Drug: OSI-906 · Drug: erlotinib

  • Placebo comparator
    Arm B: placebo plus erlotinib

    placebo BID starting on Day 1: erlotinib 150 mg QD starting on Day 1

    Drug: erlotinib · Drug: placebo

Interventions

  • Tablet administered with food and with up to 200 mL of water

  • Tablet administered at least 2 hours after food with up to 200 mL of water

    Also known as: OSI-774, Tarceva

  • Drugplacebo

    Tablet administered at least 2 hours after food with up to 200 mL of water

06

What researchers measure

Primary outcomes

  1. The Progression Free Survival (PFS) of maintenance OSI-906 plus erlotinib, or placebo plus erlotinib in patients with nonprogression following four cycles of first-line platinum-based chemotherapy for advanced NSCLC in the overall population

    PFS is defined as the time from randomization to disease progression based on RECIST v1.1 or death due to any cause whichever comes first

    Time frame: 22 months

Secondary outcomes

  1. Overall survival (OS)

    The time from the date of randomization until the documented date of death

    Time frame: 27 months

  2. Disease control Rate (DCR)

    The proportion of patients with a best overall response of continued Complete Response (CR), CR, Partial Response (PR), OR Stable Disease (SD) based on RECIST criteria

    Time frame: 27 months

  3. Best overall response rate (ORR)

    The proportion of patients with a best overall response of CR or PR based on RECIST criteria

    Time frame: 27 months

  4. Response upgrade rate (RUR)

    The proportion of patients with a response upgrade

    Time frame: 27 months

  5. Duration of response

    The time from the date of the first documented response (CR/PR) to documented progression or death due to underlying cancer

    Time frame: 27 months

  6. Safety assessed through physical examination, vital signs, clinical laboratory tests, electrocardiograms (ECG) and Adverse Events

    Time frame: 27 months

07

Study locations

69 sites
  • Site US10007
    Jacksonville, Florida 32207, United States
  • Site US10001
    Port Saint Lucie, Florida 34952, United States
  • Site US10002
    Albany, Georgia 31701, United States
  • Site US10008
    Chicago, Illinois 60612, United States
  • Site US10011
    Scarborough, Maine 04074, United States
  • Site US10004
    Greensboro, North Carolina 27403, United States
  • Site US10010
    Winston-Salem, North Carolina 27103, United States
  • Site BR55005
    Barretos, 14784-400, Brazil
  • Site BR55004
    Brasília, 70840-050, Brazil
  • Site BR55015
    Cachoeiro de Itapemirim, 29308-014, Brazil
  • Site BR55011
    Florianópolis, 88034-000, Brazil
  • Site BR55003
    Fortaleza, 60336-550, Brazil
  • Site BR55016
    Goiânia, 74605-030, Brazil
  • Site BR55006
    Ijuí, 98700-000, Brazil
  • Site BR55001
    Itajaí, 88301-220, Brazil
  • Site BR55008
    Piracicaba, 13419-155, Brazil
  • Site BR55013
    Porto Alegre, 90430-090, Brazil
  • Site BR55014
    Porto Alegre, 90610-000, Brazil
  • Site BR55012
    Ribeirão Preto, 14515-130, Brazil
  • Site BR55002
    Rio de Janeiro, 20231-050, Brazil
  • Site BR55007
    São Paulo, 01323-920, Brazil
  • Site CA11001
    Oshawa, L1G 2B9, Canada
  • Site CA11004
    Ottawa, K1H 8L6, Canada
  • Site CA11006
    Toronto, M5G 1X5, Canada
  • Site CA11002
    Toronto, M6R 1B5, Canada
  • Site DE49014
    Berlin, 10117, Germany
  • Site DE49008
    Cologne, 51109, Germany
  • Site DE49011
    Dortmund, 44145, Germany
  • Site DE49003
    Großhansdorf, 22977, Germany
  • Site DE49001
    Heidelberg, 69126, Germany
  • Site DE49002
    Hemer, 58675, Germany
  • Site DE49009
    Homburg/Saar, 66421, Germany
  • Site DE49006
    Immenhausen, 34376, Germany
  • Site DE49012
    Karlsruhe, 76137, Germany
  • Site DE49015
    Kassel, 34125, Germany
  • Site DE49010
    Lübeck, 23538, Germany
  • Site DE49013
    Mainz, 55131, Germany
  • Site DE49005
    Minden, 32429, Germany
  • Site PL48002
    Elblag, 82-300, Poland
  • Site PL48005
    Szczecin, 70-891, Poland
  • Site PL48008
    Torun, 87-100, Poland
  • Site PL48006
    Wroclaw, 53-439, Poland
  • Site RO40005
    Alba Iulia, 510077, Romania
  • Site RO40001
    Baia Mare, 490110, Romania
  • Site RO40007
    Brasov, 500366, Romania
  • Site RO40002
    Cluj-Napoca, 400015, Romania
  • Site RO40003
    Cluj-Napoca, 400015, Romania
  • Site RO40006
    Craiova, 200535, Romania
  • Site RO40004
    Hunedoara, 331057, Romania
  • Site RU70002
    Chelaybinsk, 454087, Russia
  • Site RU70010
    Kazan', 420029, Russia
  • Site RU70007
    Saint Petersburg, 194291, Russia
  • Site RU70009
    Saint Petersburg, 197089, Russia
  • Site RU70011
    Saint Petersburg, 197089, Russia
  • Site KR82007
    Busan, 602-715, South Korea
  • Site KR82006
    Hwasun, 519-809, South Korea
  • Site KR82008
    Incheon, 400-711, South Korea
  • Site KR82004
    Seongnam-si, 463-707, South Korea
  • Site KR82003
    Seoul, 120-752, South Korea
  • Site KR82005
    Seoul, 135-710, South Korea
  • Site KR82002
    Seoul, 137-701, South Korea
  • Site KR82001
    Suwon, South Korea
  • Site GB44007
    Bristol, BS2 8ED, United Kingdom
  • Site GB44006
    Dundee, DD1 9SY, United Kingdom
  • Site GB44003
    Leeds, LS9 7TF, United Kingdom
  • Site GB44002
    Leicester, LE1 5WW, United Kingdom
  • Site GB44005
    London, NW1 2PQ, United Kingdom
  • Site GB44001
    Manchester, M20 4BX, United Kingdom
  • Site GB44004
    Southampton, SO16 6YD, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Jul 2013, 27 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 27 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2010
First posted
Aug 23, 2010
StartActual
Mar 4, 2011
Primary completionActual
Jul 1, 2013
CompletionActual
Mar 11, 2015
Results delay requested
Jun 19, 2014
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01186861
Responsible party
Sponsor
First posted
Aug 23, 2010
Start date
Mar 4, 2011
Primary completion
Jul 1, 2013
Completion
Mar 11, 2015
Last update
Nov 18, 2025

Study contacts

Medical Director
study director · Astellas Pharma Global Development

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linsitinib

Start the discussion